直接口服抗凝药与低分子肝素在全髋关节置换术后静脉血栓栓塞预防中的疗效与安全性比较:系统综述与荟萃分析
该系统综述与荟萃分析纳入22项随机对照试验共28112例择期全髋关节置换术患者,比较直接口服抗凝药与低分子肝素预防静脉血栓栓塞的疗效与安全性。结果显示直接口服抗凝药组静脉血栓栓塞风险较低(OR 0.62),深静脉血栓风险亦较低(OR 0.60),但总体出血风险较高(OR 1.19);仅限英国许可的抗凝药及剂量时,出血风险无差异。
要点
- 直接口服抗凝药较低分子肝素降低全髋关节置换术后静脉血栓栓塞和深静脉血栓风险。
- 总体出血风险直接口服抗凝药较高,但仅限英国许可药物及剂量时无差异。
- 再手术风险和死亡率两组无差异。
核心结论
- 对于英国许可的抗凝药及剂量,直接口服抗凝药较低分子肝素降低择期全髋关节置换术后静脉血栓栓塞风险且不增加出血风险。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和CENTRAL从建库至2025年12月13日,纳入比较低分子肝素与直接口服抗凝药用于择期全髋关节置换术后静脉血栓栓塞预防的随机对照试验,共22项随机对照试验、28112例参与者。
主要发现
- 直接口服抗凝药组静脉血栓栓塞风险低于低分子肝素组(OR 0.62,95%CI 0.47至0.82;p=0.002),主要由深静脉血栓风险降低驱动(OR 0.60,95%CI 0.42至0.86;p=0.008)。
- 仅限英国许可的抗凝药及剂量亚组分析结果一致。
- 直接口服抗凝药组总体出血风险较高(OR 1.19,95%CI 1.03至1.38;p=0.023),但仅比较英国许可的抗凝药及剂量时无差异(OR 1.06,95%CI 0.95至1.18;p=0.279)。
- 再手术风险(OR 1.21,95%CI 0.75至1.93;p=0.351)和死亡率(OR 1.03,95%CI 0.46至2.33;p=0.937)两组无差异。
临床怎么用
- 对于择期全髋关节置换术后静脉血栓栓塞预防,可考虑使用英国许可的直接口服抗凝药及剂量,以降低静脉血栓栓塞风险而不增加出血风险。
局限性
- 需要新的临床试验比较英国许可的直接口服抗凝药与低分子肝素在现代术后康复方案下的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To evaluate differences in the efficacy and safety of low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) used for venous thromboembolism (VTE) prophylaxis after elective total hip arthroplasty (THA). METHODS: This systematic review and meta-analysis reviewed MEDLINE, Embase, and CENTRAL from conception to 13 December 2025, for any randomized controlled trials (RCTs) comparing the efficacy (VTE risk) and safety (bleeding risk) of LMWH and DOACs after elective THA. Pooled odds ratios (ORs) of VTE, bleeding, reoperation, and mortality risks were assessed. RESULTS: A total of 22 RCTs involving 28,112 participants were included. The risk of VTE in the DOAC group was lower compared with the LMWH group (OR 0.62 (95% CI 0.47 to 0.82); p = 0.002), driven by a reduction in deep vein thrombosis (DVT) risk (OR 0.60 (95% CI 0.42 to 0.86); p = 0.008). The findings remained consistent in the subgroup analysis restricted to anticoagulants and dosages licensed for use in the UK. Overall bleeding risk was higher in the DOAC group (OR 1.19 (95% CI 1.03 to 1.38); p = 0.023), but no difference was seen when comparing only UK-licensed anticoagulants and doses (OR 1.06 (95% CI 0.95 to 1.18); p = 0.279). Reoperation risk (OR 1.21 (95% CI 0.75 to 1.93); p = 0.351) and mortality (OR 1.03 (95% CI 0.46 to 2.33); p = 0.937) did not differ between groups. CONCLUSION: DOACs reduce the risk of VTE and DVT following elective THA compared with LMWH without increasing bleeding risk, for UK-licensed agents and doses. Switching to DOACs could save the NHS £8.6 million per year. New clinical trials are needed to compare the safety and efficacy of UK-licensed DOACs and LWMH with modern postoperative rehabilitation protocols.
引用
- Mohammad HR, Rahman A, Muhammad IM, et al. A comparison of the efficacy and safety of direct oral anticoagulants with low molecular weight heparin for venous thromboembolism prophylaxis after total hip arthroplasty : a systematic review and meta-analysis. Bone Joint J. 2026. PMID: 42966367. doi:10.1302/0301-620X.108B11.BJJ-2026-0451.R2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。